Biocon Limited (BOM: 532523)
India
· Delayed Price · Currency is INR | Market Cap | 480.58B |
| Revenue (ttm) | 148.94B |
| Net Income (ttm) | 14.39B |
| Shares Out | n/a |
| EPS (ttm) | 12.00 |
| PE Ratio | 33.39 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | Jul 5, 2024 |
| Volume | 215,880 |
| Average Volume | 275,707 |
| Open | 396.55 |
| Previous Close | 392.70 |
| Day's Range | 390.75 - 402.90 |
| 52-Week Range | 244.40 - 402.90 |
| Beta | n/a |
| RSI | 65.30 |
| Earnings Date | Jan 29, 2025 |
About Biocon
Biocon Limited, together with its subsidiaries, engages in the manufacture and sale of biotechnology products and research services in India, Brazil, Singapore, and internationally. It operates through four segments: Generics, Novel Biologics, Biosimilars, and Research Services. The company offers generic formulations and API products, including anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology, and other products; novel biologics products, such as head and neck cancer molecule; novel pipeline products comprising psor... [Read more]
Financial Performance
In 2023, Biocon's revenue was 147.56 billion, an increase of 32.05% compared to the previous year's 111.74 billion. Earnings were 10.23 billion, an increase of 120.99%.
Financial StatementsNews
CCI penalises investment manager of Goldman Sachs AIF for failing to notify Biocon deal
The Competition Commission of India fined Goldman Sachs AIMPL Rs 40 lakh for not notifying it about a deal that included acquiring optionally convertible debentures in Biocon Biologics, providing sign...
Stock Market Update, January 16: BSE and Biocon hit new 52-week highs today
Indian stock markets had another positive session on January 16, 2025, with the benchmark indices continuing their upward momentum. The Nifty 50 and Sensex indices both registered notable gains, with ...
Pharma sector stocks: Biocon (+3.10%), Aurobindo Pharma (+0.48%), Divis Labs (+0.39%) rise; Mankind Pharma (-1.43%) leads losers
Pharma sector stocks witnessed mixed movement in early trade today, with selective buying in mid-cap stocks while large-cap players faced profit booking. Stock Performance (as of 10:28 AM): Biocon: ₹3...
Pharma Stocks Today: Biocon surges 4.41%, Mankind Pharma up 1.85%; Glaxo and Abbott India decline
Pharma stocks showed mixed trends in early trading as of 9:24 AM today. Biocon led the gainers, rising 4.41% to trade at ₹381.30, while Mankind Pharma climbed 1.85%, trading at ₹2,644.05. Top Gainers:...
Biocon shares surge nearly 4% as HSBC upgrades to ‘Buy’
Biocon Ltd saw its shares rise nearly 4% in early trading, reaching ₹379, following HSBC’s upgrade of the stock to a ‘Buy’ rating. The brokerage significantly raised its target price for Biocon from ₹...
HSBC upgrades Biocon to ‘Buy’, raises target price to ₹430
HSBC has upgraded Biocon to a ‘Buy’ rating, raising its target price from ₹290 to ₹430, citing the company’s operational turnaround fueled by upcoming biosimilar launches and a recovery in generics sa...
Biocon shares surge 4% today; Motilal Oswal upgrades stock to Buy
Shares of Biocon surged 4% today following an upgrade by Motilal Oswal to a “Buy” rating, with a target price of ₹430. The upgrade reflects improved regulatory visibility, operational advancements, an...
Pharma stocks: Biocon up 3.84% on US FDA nod for Malaysia unit; Divi’s Lab gains 0.61%, Mankind Pharma slips 3.75%, GlaxoSmithKline drops 2.42%
At 10:13 AM, pharma stocks showed mixed trends, with Biocon emerging as the top gainer. The stock surged 3.84% to ₹374.80 after the company announced that its Malaysia insulin facility received cleara...
Biocon shares jump 3% as U.S. FDA classifies Johor Bahru facility as VAI
Biocon shares surged by 3% after the company announced that the U.S. Food and Drug Administration (FDA) classified its biologics manufacturing site in Johor Bahru, Malaysia, as “Voluntary Action Indic...
Top stocks to watch in trade today: DMart, PCBL, Biocon, Just Dial, Waaree Energies and more
Markets are expected to remain volatile today, continuing the downward trend observed last week. On Friday, the BSE Sensex ended 241 points lower at 77,378.91, a dip of 0.30%. Meanwhile, the Nifty50 d...
BofA maintains buy on Biocon, check target share price here
Bank of America (BofA) has reaffirmed its buy rating on Biocon, increasing the target price to ₹435 from ₹400. The current market price (CMP) of the stock is ₹360, implying significant upside potentia...
Biocon Update: U.S. FDA classifies Johor Bahru facility as VAI
Biocon Limited has announced that the U.S. Food and Drug Administration (FDA) has classified its biologics manufacturing site in Johor Bahru, Malaysia, as “Voluntary Action Indicated” (VAI). This deci...
Pharma stocks: Dr. Reddy’s up 1.70%, Biocon down 2.17%, Lupin falls 2.18%
As of 10:58 AM, pharma stocks exhibited mixed performance. Here are the key highlights: Gainers: Dr. Reddy’s Laboratories: Leading the gains with a 1.70% rise, trading at ₹1,374.55. Cipla: Slight upti...
Biocon shares rise 3% as subsidiary secures Japanese PMDA approval for Ustekinumab biosimilar
Shares of Biocon Ltd. surged by 3% today following its subsidiary Biocon Biologics Ltd.’s (BBL) announcement of a major regulatory milestone. The Pharmaceuticals and Medical Devices Agency (PMDA) of J...
Biocon Biologics secures PMDA approval for Ustekinumab biosimilar in Japan
Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, has achieved a significant milestone with the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan granting regulatory approval for its Us...
Pharma sector stocks performance: Ipca Labs gains 1.23%, Biocon up 0.84%, Sun Pharma and Torrent Pharma slip over 1%
Pharma sector stocks displayed a mixed trend as of 10:33 AM. Ipca Labs led the gainers with a 1.23% rise, followed by Biocon at 0.84% and Dr. Reddy’s at 0.65%. On the downside, Sun Pharma (-1.15%), Au...
Aurobindo Pharma (+1.58%), Mankind Pharma (+1.48%), Zydus Lifesciences (+0.91%) lead pharma stock gains
As of 10:00 AM, pharma stocks are trading mixed, with Aurobindo Pharma, Mankind Pharma, and Zydus Lifesciences emerging as top gainers. Meanwhile, Biocon (-0.72%), Ipca Labs (-0.40%), and Dr. Reddy’s ...
Biocon receives VAI status from US FDA for Bengaluru API facility
Biocon has recently informed exchanges that its Bengaluru API facility (Site 1) has received a Voluntary Action Indicated (VAI) status from the U.S. Food and Drug Administration (US FDA). This follows...
Biocon shares jump 2% on EU approval for Liraglutide formulation
Biocon Limited’s shares surged by 2% after the company and its European partner Zentiva have achieved a major milestone with EU approval for their Liraglutide formulation. The companies secured Europe...
Biocon and its European partner Zentiva secure EU approval for Liraglutide formulation
Biocon Limited and its European partner Zentiva have achieved a major milestone with EU approval for their Liraglutide formulation. This generic version of Victoza® (for Type-2 Diabetes) and Saxenda® ...
Stocks to watch, December 16: Biocon, Lupin, Bharat Forge, Radico Khaitan, Dixon Tech, and Aurobindo Pharma and more in focus today
Here are our stocks to watch today on Dec 16, 2024: Biocon, Lupin, Bharat Forge, Radico Khaitan, Dixon Tech, Aurobindo Pharma, PVR Inox, RITES, Godrej Agrovet, HBL Power, Borosil Renewables, JK Paper ...
Pharma stocks: Divi’s Lab (+0.82%), IPCA (+0.83%) rise; Biocon (-1.86%), Glaxo (-1.44%) decline
The pharma sector showed a mixed trend during intraday trading as of 11:25 AM, with select stocks gaining while others faced selling pressure. Key Performances: Gaining Stocks: IPCA Laboratories: Up 0...
Pharma Stocks: Cipla down nearly 2%, Ajanta Pharma down 1.45%, Abbott India up 1.27%
The Nifty Pharma index was trading 0.25% lower at 22,389.10 during today’s session, as losses in Cipla, Biocon, and Aurobindo Pharma weighed on the sector, despite gains in Abbott India and Ajanta Pha...
Biocon shares surge nearly 3% after FDA nod for Yesintek, a biosimilar to Stelara
Shares of Biocon surged by 2.7% to Rs 375 on Monday following the U.S. FDA’s approval for Yesintek, a biosimilar to Johnson & Johnson’s blockbuster arthritis drug, Stelara. This approval marks a signi...
Stocks to watch today: Maruti Suzuki, TVS Motor, Biocon, DLF, RVNL, RBL, Cipla, Home First, Cochin Shipyard in focus
The stock market is abuzz with updates across several companies today. Below are the highlights in the green and red zones: Maruti Suzuki: November sales saw a minor beat, driven by a strong performan...